Zobrazeno 1 - 10
of 77
pro vyhledávání: '"I Alonso-Abreu"'
Autor:
M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i50-i54
Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r
Autor:
C Rubín De Célix, J Martín de Carpi, G Pujol, L Palomino, M Velasco, R Martín-Masot, V M Navas-López, E Ricart, M J Casanova, A Rodríguez Martínez, E Leo, A Alcaraz, M Mañosa, V Hernández, R Fernández, C Sánchez, L Menchén, F Mesonero, M Barreiro-De Acosta, N Martinon, C Tejido Sandoval, A Rendo Vázquez, P Corsino, R Vicente, A Hernández-Camba, J R Alberto Alonso, I Alonso-Abreu, A M Castro Millán, L Peries Reverter, B Castro, E Fernández-Salgado, M M Busto Cuiñas, J M Benítez, L Madero, F Clemente, S Riestra, S Jiménez-Treviño, M Boscá, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i37-i39
Background It has been suggested that the transition of patients from paediatric to adult care units may be key in the outcomes of inflammatory bowel disease (IBD). However, the impact of transition in real clinical practice has been barely studied.
Autor:
I Bastón Rey, C Calvino Suárez, A M Luque, B Caballol, C Soutullo, A Bravo, A Castaño, B Gros, L Bernal, M T Diz Lois, H Alonso Galán, F Cañete, B Castro, P Pérez Galindo, C González Muñoza, I El Hajra, P Martínez Montiel, I Alonso Abreu, F Mesonero, M González Vivo, L Peries, E Martín Arranz, C Abril, I Marín Jiménez, R Baltar, M Vicuna, N Moreno, E Brunet, C Rubín de Célix, I Fajardo, N Cruz, M Rojas Feria, A Fernández Clotet, M Gimeno, Y Zabana, C Suárez Ferrer, I Rodríguez Lago, M Barreiro de Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i054-i056
Background Limited data is available of the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). The aim of our study was to describe the natural history of pre-existing IBD and de novo IBD after SOT. Method
Autor:
Cristina Rubín de Célix, Javier Martín-de-Carpi, Gemma Pujol-Muncunill, Laura María Palomino, Marta Velasco Rodríguez-Belvís, Rafael Martín-Masot, Víctor Manuel Navas-López, Elena Ricart, María José Casanova, Alejandro Rodríguez Martínez, Eduardo Leo-Carnerero, Alba Alcaraz, Miriam Mañosa, Vicent Hernández, María Consuelo Cobelas Cobelas, César Sánchez, Luis Menchén, Francisco Mesonero, Manuel Barreiro-De Acosta, Nazareth Martínon, Coral Tejido Sandoval, Alicia Rendo Vázquez, Pilar Corsino, Raquel Vicente, Alejandro Hernández-Camba, José Ramón Alberto Alonso, I. Alonso-Abreu, Ana María Castro Millán, Laia Peries Reverter, Beatriz Castro, Estela Fernández-Salgado, M Mercedes Busto Cuiñas, José Manuel Benítez, Lucía Madero, Fernando Clemente, Sabino Riestra, Santiago Jiménez- Treviño, Maia Boscá-Watts, Elena Crehuá-Gaudiza, Marta Calvo Moya, José María Huguet, Ester-María Largo-Blanco, Leticia González Vives, Rocío Plaza, Iván Guerra, Josefa Barrio, Laura Escartín, Erika Alfambra, Noelia Cruz, M Carmen Muñoz, María Guadalupe Muñoz Pino, Manuel Van Domselaar, Belén Botella, David Monfort Miquel, M Carmen Rodríguez Grau, Agustín De La Mano, Yolanda Ber, María Calvo Iñiguez, Teresa de Jesús Martínez-Pérez, María Chaparro, Javier P. Gisbert
Publikováno v:
Gastroenterología y Hepatología. 46:S73
Autor:
L Ramos Lopez, R Ramos-Díaz, I Alonso-Abreu, I Mourani-Padron, M Carrillo-Palau, M C Reygosa, S Medina-Chico, F Gutierrez-Nicolas, G J Nazco-Casariego, M Hernandez-Guerra
Publikováno v:
Journal of Crohn's and Colitis. 17:i644-i644
Background Therapeutic drug monitoring (TDM) is a valuable tool to optimize anti-TNF biologics in inflammatory bowel disease (IBD). However, for the non-anti-TNF agents (such as Ustekinumab-UST- an anti-IL12/23) TDM value and evidence in real-world I
Autor:
L Ramos Lopez, A Hernández, M Carrillo-Palau, A Hernández-Camba, I Alonso-Abreu, C Reygosa, M Vela, G E Rodríguez, Y González-Mendez, C Tardillo, L Arranz, F Benítez-Zafra, M Hernández-Guerra
Publikováno v:
Journal of Crohn's and Colitis. 16:i271-i272
Background During the COVID-19 pandemic, outpatient activity and the performance of complementary tests have been limited in order to optimize health care resources in patients with SARS-CoV2 infection according to the incidence of cases in each time
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celio, I Alonso Abreu, L Melcarne, R Plaza Santos, M Marques Cami, A Caballero Mateos, C Gomez Diez, M Calafat, H Alonso Galan, P Vega Vilaamil, B Castro Sensosian, A Guerro Moya, C Y Rodriguez Diaz, K Spicakova, N Manceñido Marcos, G Molina, L De Castro, A Rodriguez Angulo, L Cuevas del Campo, M C Rodriguez Grau, F Ramirez, B Gomez Pastrana, I Gonzalez Partida, B Botella Mateu, E Peña Gonzalez, E Iyo, A Elosua Gonzalez, M Mañosa Ciria, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i449-i450
Background The use of biological drugs for the treatment of IBD in elderly patients is becoming more frequent in our environment. However, given the greater risk of these patients to develop related adverse effects, the profile of the patients in who
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, M D Martin-Arranz, A Lopez Sanroman, A Fernandez-Clotet, V Merino Murgui, C Calviño Suarez, P Florez, M E Lobato Matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, P G Elena, E Iyo, A Elosua Gonzalez, E Saiz, L Hernandez Villalba, P Perez Galindo, L Torrealba Medina, S Monsalve Alonso, J A Olmos Jerez, C Dueñas Sadornil, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i478-i479
Background Biological treatments used for the treatment of inflammatory bowel disease (IBD) have demonstrated their efficacy and safety, although these results were obtained from studies that mostly include young people generally included in clinical
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, A Lopez Sanroma, M D Martin-Arranz, A Fernández-Clotet, V Merino Murgui, C Calviño Suárez, P Florez, M E Lobato matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, R Plaza Santos, M Marques Cami, A Caballero Mateos, C Gómez Díez, M Calafat, H Alonso Galan, P Vega Villaamil, B Castro Senosiain, A Guerro Moya, C Y Rodriguez Diaz, K Spicakova, N Manceñido Marcos, G Molina, L De Castro, M Mañosa Ciria, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i400-i401
Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of tumors and / or serious infections. These events are generally more frequent in elderly patients, so th
Autor:
L Ramos Lopez, M Carrillo-Palau, I Alonso-Abreu, C Reygosa, N Hernández-Buylla, C Amaral, A Hernández, F Benítez-Zafra, F Pérez-González, H Quintana-Díaz, M Hernández-Guerra
Publikováno v:
Journal of Crohn's and Colitis. 16:i592-i593
Background Vaccination against COVID19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In Spain, by October 2021, 87.9% of the target population, including IBD patients had received the compl